The efficacy of duloxetine (60 mg qd) in the treatment of painful physical symptoms in patients with major depressive disorder

Wohlreich, MM; Mallinckrodt, C.; Lu, Yunfeng; Detke, MJ

doi:10.1016/s0022-3999(03)00200-9

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Duloxetine (Cymbalta) also inhibits the reuptake of serotonin and norepinephrine and to a greater extent than its negative enantiomer (LY248685 -; Wong et al, 1993). It is commonly used at daily doses of 60-120 mg, and is often started at a dose of 30 mg. To date, duloxetine has not been approved by the FDA for the treatment of depression, but is expected to be given approval in 2004.…”

Section: Serotonin and Norepinephrine Reuptake Inhibitors (Snris)mentioning

confidence: 99%

Monoaminergic‐based Pharmacotherapy for Depression

Papakostas¹,

Fava²

2005

Biology of Depression

View full text Add to dashboard Cite

Although recent advances in neuropharmacology, neuroendocrinology, molecular biology, and pharmacogenetics have been instrumental in bringing about potential treatments for depression which are fundamentally unrelated to their predecessors, including substance P antagonists, glutaminergic agents, and corticotropinreleasing factor (CRF) antagonists, nevertheless it was agents that influenced the function of monoamine receptors and transporters that were discovered initially by serendipity and then developed as treatments for depression. The development of such compounds also served as a framework for the understanding of depression as a medical illness affecting brain functioning. As a result of these efforts, our field has gained further understanding of the role of monoamines in depression. In previous chapters, the relevance of monoamines in the underlying pathophysiology of depression was reviewed. In the following chapter we will focus on describing the contemporary role of monoaminergic agents in the treatment of depression. 6.

show abstract

Section: Serotonin and Norepinephrine Reuptake Inhibitors (Snris)mentioning

confidence: 99%